Literature DB >> 9564500

Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis.

G W Wortmann1, S L Fraser, N E Aronson, C Davis, R S Miller, J D Jackson, C N Oster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9564500     DOI： 10.1086/517634

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  US Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

2.  Leishmaniasis at the End of the Millennium.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

3.  Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.

Authors:  Glenn Wortmann; Michael Zapor; Roseanne Ressner; Susan Fraser; Josh Hartzell; Joseph Pierson; Amy Weintrob; Alan Magill
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

4.  A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.

Authors:  Roshan Ramanathan; Kawsar R Talaat; Daniel P Fedorko; Siddhartha Mahanty; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.